Literature DB >> 17544572

Local progression among men with conservatively treated localized prostate cancer: results from the Transatlantic Prostate Group.

James A Eastham1, Michael W Kattan, Paul Fearn, Gabrielle Fisher, Daniel M Berney, Tim Oliver, Christopher S Foster, Henrik Møller, Victor Reuter, Jack Cuzick, Peter Scardino.   

Abstract

OBJECTIVES: Men with clinically detected localized prostate cancer treated without curative intent are at risk of complications from local tumor growth. We investigated rates of local progression and need for local therapy among such men.
METHODS: Men diagnosed with prostate cancer during 1990-1996 were identified from cancer registries throughout the United Kingdom. Inclusion criteria were age < or =76 yr at diagnosis, PSA level < or =100 ng/ml, and, within 6 mo after diagnosis, no radiation therapy, radical prostatectomy, evidence of metastatic disease, or death. Local progression was defined as increase in clinical stage from T1/2 to T3/T4 disease, T3 to T4 disease, and/or need for transurethral resection of the prostate (TURP) to relieve symptoms >6 mo after cancer diagnosis.
RESULTS: The study included 2333 men with median follow-up of 85 mo (range: 6-174). Diagnosis was by TURP in 1255 men (54%), needle biopsy in 1039 (45%), and unspecified in 39 (2%). Only 29% were treated with hormonal therapy within 6 mo of diagnosis. Local progression occurred in 335 men, including 212 undergoing TURP. Factors most predictive of local progression on multivariable analysis were PSA at diagnosis and Gleason score of the diagnostic tissue (detrimental), and early hormonal therapy (protective). We present a nomogram that predicts the likelihood of local progression within 120 mo after diagnosis.
CONCLUSIONS: Men with clinically detected localized prostate cancer managed without curative intent have an approximately 15% risk for local progression within 10 yr of diagnosis. Among those with progression, the need for treatment is common, even among men diagnosed by TURP. When counseling men who are candidates for management without curative intent, the likelihood of symptoms from local progression must be considered.

Entities:  

Mesh:

Year:  2007        PMID: 17544572      PMCID: PMC2646888          DOI: 10.1016/j.eururo.2007.05.015

Source DB:  PubMed          Journal:  Eur Urol        ISSN: 0302-2838            Impact factor:   20.096


  20 in total

1.  Immediate versus deferred androgen deprivation treatment in patients with node-positive prostate cancer after radical prostatectomy and pelvic lymphadenectomy.

Authors:  Edward M Messing; Judith Manola; Jorge Yao; Maureen Kiernan; David Crawford; George Wilding; P Anthony di'SantAgnese; Donald Trump
Journal:  Lancet Oncol       Date:  2006-06       Impact factor: 41.316

2.  Study design of the Medical Therapy of Prostatic Symptoms (MTOPS) trial.

Authors:  Oliver M Bautista; John W Kusek; Leroy M Nyberg; John D McConnell; Raymond P Bain; Gary Miller; E David Crawford; Steven A Kaplan; Stephen A Sihelnik; Michael K Brawer; Hebert Lepor
Journal:  Control Clin Trials       Date:  2003-04

3.  Incidence of initial local therapy among men with lower-risk prostate cancer in the United States.

Authors:  David C Miller; Stephen B Gruber; Brent K Hollenbeck; James E Montie; John T Wei
Journal:  J Natl Cancer Inst       Date:  2006-08-16       Impact factor: 13.506

4.  The need for hospital care of patients with clinically localized prostate cancer managed by noncurative intent: a population based registry study.

Authors:  K Brasso; S Friis; K Juel; T Jørgensen; P Iversen
Journal:  J Urol       Date:  2000-04       Impact factor: 7.450

5.  Latent carcinoma of prostate at autopsy in seven areas. The International Agency for Research on Cancer, Lyons, France.

Authors:  N Breslow; C W Chan; G Dhom; R A Drury; L M Franks; B Gellei; Y S Lee; S Lundberg; B Sparke; N H Sternby; H Tulinius
Journal:  Int J Cancer       Date:  1977-11-15       Impact factor: 7.396

6.  A randomized trial comparing radical prostatectomy with watchful waiting in early prostate cancer.

Authors:  Lars Holmberg; Anna Bill-Axelson; Fred Helgesen; Jaakko O Salo; Per Folmerz; Michael Häggman; Swen-Olof Andersson; Anders Spångberg; Christer Busch; Steg Nordling; Juni Palmgren; Hans-Olov Adami; Jan-Erik Johansson; Bo Johan Norlén
Journal:  N Engl J Med       Date:  2002-09-12       Impact factor: 91.245

7.  Quality of life after radical prostatectomy or watchful waiting.

Authors:  Gunnar Steineck; Fred Helgesen; Jan Adolfsson; Paul W Dickman; Jan-Erik Johansson; Bo Johan Norlén; Lars Holmberg
Journal:  N Engl J Med       Date:  2002-09-12       Impact factor: 91.245

8.  Natural history of early, localized prostate cancer.

Authors:  Jan-Erik Johansson; Ove Andrén; Swen-Olof Andersson; Paul W Dickman; Lars Holmberg; Anders Magnuson; Hans-Olov Adami
Journal:  JAMA       Date:  2004-06-09       Impact factor: 56.272

9.  Prevalence of prostate cancer among men with a prostate-specific antigen level < or =4.0 ng per milliliter.

Authors:  Ian M Thompson; Donna K Pauler; Phyllis J Goodman; Catherine M Tangen; M Scott Lucia; Howard L Parnes; Lori M Minasian; Leslie G Ford; Scott M Lippman; E David Crawford; John J Crowley; Charles A Coltman
Journal:  N Engl J Med       Date:  2004-05-27       Impact factor: 91.245

10.  Long-term outcome among men with conservatively treated localised prostate cancer.

Authors:  J Cuzick; G Fisher; M W Kattan; D Berney; T Oliver; C S Foster; H Møller; V Reuter; P Fearn; J Eastham; P Scardino
Journal:  Br J Cancer       Date:  2006-11-06       Impact factor: 7.640

View more
  7 in total

1.  Risk stratification of men choosing surveillance for low risk prostate cancer.

Authors:  Kenneth S Tseng; Patricia Landis; Jonathan I Epstein; Bruce J Trock; H Ballentine Carter
Journal:  J Urol       Date:  2010-03-20       Impact factor: 7.450

2.  Impact of race on survival in patients with clinically nonmetastatic prostate cancer who deferred primary treatment.

Authors:  Michael Koscuiszka; David Hatcher; Paul J Christos; Amy E Rose; Holly S Greenwald; Ya-lin Chiu; Samir S Taneja; Madhu Mazumdar; Peng Lee; Iman Osman
Journal:  Cancer       Date:  2011-10-21       Impact factor: 6.860

3.  PRKC-ζ Expression Promotes the Aggressive Phenotype of Human Prostate Cancer Cells and Is a Novel Target for Therapeutic Intervention.

Authors:  Sheng Yao; Alix Bee; Daniel Brewer; Andrew Dodson; Carol Beesley; Youqiang Ke; Laurence Ambroisine; Gabrielle Fisher; Heinrich Møller; Tim Dickinson; Patricia Gerard; Lu-Yu Lian; Janet Risk; Brian Lane; Paul Smith; Victor Reuter; Daniel Berney; Christine Gosden; Peter Scardino; Jack Cuzick; Mustafa B A Djamgoz; Colin Cooper; Christopher S Foster
Journal:  Genes Cancer       Date:  2010-05

4.  Increased aPKC Expression Correlates with Prostatic Adenocarcinoma Gleason Score and Tumor Stage in the Japanese Population.

Authors:  Anthony S Perry; Bungo Furusato; Raymond B Nagle; Sourav Ghosh
Journal:  Prostate Cancer       Date:  2014-04-29

5.  Hsp-27 expression at diagnosis predicts poor clinical outcome in prostate cancer independent of ETS-gene rearrangement.

Authors:  C S Foster; A R Dodson; L Ambroisine; G Fisher; H Møller; J Clark; G Attard; J De-Bono; P Scardino; V E Reuter; C S Cooper; D M Berney; J Cuzick
Journal:  Br J Cancer       Date:  2009-08-25       Impact factor: 7.640

Review 6.  A new algorithm in patients with elevated and/or rising prostate-specific antigen level, minor lower urinary tract symptoms, and negative multisite prostate biopsies.

Authors:  Koenraad van Renterghem; Gommert Van Koeveringe; Ruth Achten; Philip van Kerrebroeck
Journal:  Int Urol Nephrol       Date:  2009-06-03       Impact factor: 2.370

7.  Ki-67 and outcome in clinically localised prostate cancer: analysis of conservatively treated prostate cancer patients from the Trans-Atlantic Prostate Group study.

Authors:  D M Berney; A Gopalan; S Kudahetti; G Fisher; L Ambroisine; C S Foster; V Reuter; J Eastham; H Moller; M W Kattan; W Gerald; C Cooper; P Scardino; J Cuzick
Journal:  Br J Cancer       Date:  2009-03-24       Impact factor: 7.640

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.